initi outperform pt
feel libreat stock mile high
initi coverag share outperform rate
pt tsr phenomen run share
despit run share under-perform peer group
year basi see room share run
st begin appreci abt top-line acceler
rang one best new product cycl year visibl
see key debat shape stori
outlook legaci cardio stj busi ail
given massiv share loss proprietari survey show
stabil grow modestli along
confirm rx icm mitraclip expect improv cardio drive
bp growth acceler overal
libr launch us vs nutrit think libr us launch could
 mm revenue contributor along
nutrit get back lsd growth contribut bp
improv overal growth
alr synergi ep power think alr synergi like
execut spot yr along alr provid bp
om expans oppti next year provid highli
visibl path teen tsr scarciti mega cap med-tech
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate price-to-earnings basi
translat premium vs in-lin average
compar average average
downsid risk inabl regain share could
pressur margin headwind nutrit continu price
pressur privat label alr execut risk uncertain
em fx environ difficult model given broad exposur
em countri could off-set synergi disappoint number vs st
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
feel libreat stock mile high
last page report import disclosur regard stock report
famili
tabl content
debat base cardio stj biz inflect
debat abt mid term ep profil alr
iv thesi risk
diversifi med-tech co exposur consum rx dx
ceo mile white year includ year
chairman ceo
cfo brian yoor year experi includ
year
medic devic bolster stj
acquisit largest piec sale
nutrit diagnost
establish pharmaceut compris
remaind portfolio
pharma spin
epd sale give
consist om expans post spin
share outperform ytd u/p yr basi
spin
share rebound street
gain clariti alr
acquisit sale growth
investor debat head
share gain structur heart make
outlook legaci freestyl libr power
nutrit soft think alin contribut
abt mid term ep profil follow aler alr
legaci stj growth seem steadi eddi lsd rang underli segment paint vastli differ pictur
lack mri safe portfolio
question head
 stabil
much neuromod
new product
drive growth
rm rev dd straight yr
off-set strong dd growth area
rm highest gross margin biz impact
bottom-line brutal
note stand abbott cardiovascular neuromodul
chart compani data evercor isi
debat bp rm share lost due mri safe recal
lack mri safe label prematur batteri deplet recal result bp share loss past year
first fda approv
recal due
mri safe portfolio result
market share gain
market share loss
subsequ fear abt/stj batteri
deplet exacerb share loss
abt mri safe pacemak approv
earli feb management note
regain bp share
total loss bp
recent receiv fda approv
mri safe sept
approv earli
batteri deplet concern abat still headwind
much lost share regain new mri safe approv
offset investor awar
debat evrisi survey gaug physician view
mix implant amongst respond compani
given import rm segment conduct survey
gaug physician expect view potenti
survey conduct decemb physician
time digest abt latest mri fda
respond stem not-for-profit
larger hospit bed repres major
profit
chart evercor isi cardiac rhythm manag survey
debat survey show grow
respond think batteri deplet concern
awar abt mri safe high amongst ep
decis purchas implant mri safe icd/crt-d
question awar stj receiv fda approv
mri compat label ellips
expect gain share
could benefit mm approv
question expect stj ellips mri-saf
gain share next month
chart evercor isi cardiac rhythm manag survey
wt average basi
gain mo
 mm gross share gain
assum similar loss crt post
approv total gain could mm
debat stabil drive bp growth
net basi believ abl stem bleed grow slightli
share gain
loss micra
share loss
share gain
note assum crt-d mri approv share captur math
headwind bp impact top-line abat
impact abt/stj growth
estim share loss impact
growth bp
stabl posit
help top-line growth bp
headwind abat contribut meaning abt top-line growth
could face replac headwind
demand pull forward due abt warranti offer even assum flat
would translat bp top-line growth
debat mitraclip continu grow strong dd
survey show low teen center growth
conduct survey intervent cardiologist
gain view mitraclip potenti
mitraclip devic approv treat
mitraclip rev doubl
mm mm current
survey conduct decemb
growth
center
growth
doc perform mitraclip could increas
lastli indic exp also meaning driver
question current perform mitraclip procedur
coapt clinic trial mitraclip function mitral
perform
survey show
could increas doc
plan use mitraclip vs
chart evercor isi intervent cardiologist ic survey
competit mitraclip seem year away
regurgit fmr result expect
current mitraclip procedur
perform patient fmr
indic expans could nearli tripl mitraclip
oppti
ew enter eu market pascal
us trial begin
mitraclip continu grow strong dd add bp overal growth
debat lvad neuromod also contribut
within lvad expect trade share btt vs dt overal growth trend dd rang
compani data evercor isi
lvad left ventricular assist devic market seen
doubl digit growth market sole player
receiv fda approv dt destin therapi
label hvad system late septemb
receiv btt bridg transplant label approv
fda heartmat system late april
gain share implant done
dt expect share gain btt off-set
histor dt btt approv lead similar amount
revenue increas growth rate impact larger base
new product drove bp share gain neuromodwhil growth moder still healthi
abt/stj got drg feb burst oct approv
spinal cord stim infin db oct approv
neuromod grew drove bp share gain
competit increas dec vercis db
recent approv fda
tough comp competit like impact growth
overal neuromod continu grow
burst drg seen differenti
expect lvad neuromod contribut bp mm total growth
debat confirm rx give entri anoth high growth market
mdt linq grew mm biz past yearsabt entri bode well market expans awar
abbott receiv fda approv confirm rx
implant cardiac monitor icm late octob
previous player mm
given market significantli under-penetrated
believ abt entri like expand total
address market rather shift share meaning
tavr analog enter us market
penetr could add mm rev
mm sale
medtron analyst day
confirm rx excit new
opportunitycould possibl add bp
interest question whether
could increas pull-through
pacemak implant similar
happen would impli
greater benefit top-line
debat potenti tavr laa us intro bode well
portico tavr set continu growth
amplatz pfo laa also increment driver
portico continu ramp eu market like
amplatz amulet laa pfo occlud
one key beneficiari bsx lotu
lotu mm sale prior
withdrawn form eu market earli feb
avail ce mark countri
pfo occlud fda approv late
us ide trial amplatz laa start
us pivot trial complet enrol follow
though small product continu show doubl digit
current on-going year follow
potenti us launch could earli
time-frame would allow entri bn us
cardiomem sale still aliv
heart failur monitor system wirelessli measur
monitor pulmonari arteri pressur heart rate
experienc reimburs pushback certain
medicar administr contractor decid
cover devic
said cardiomem continu grow sale
doubl digit small base
remind bsx watchman laa rev
tripl mm post us launch
product repres mm
annual sale grow doubl
digit meaning overal
abt growth product could open
larg tam tavr laa
potenti launch us
debat diabet growth inflect driven libr
diabet tale two citi base biz declin off-set ou libr ramp
ou strength driven freestyl
declin us
impact competit
diabet current bn busi
compris total revenu
busi challeng year given
glucos monitor involv finger prick
libr game changer
off-set base bgm declin
contribut overal segment growth
freestyl libr elimin routin finger prick calibr perceiv major benefit
libr consist small sensor attach back arm
sensor last day
handheld reader scan data give point estim finger
prick involv patient scan often want
annual cost freestyl libr could cheaper assum
insur coverag tradit cgm
flash cgm freestyl libr ideal type diabet patient
dont need pump
receiv us approv recent libr key product
debat freesty libr add mm rev conserv
us freestyl libr promis solid contributor top-line medium term
differenti label versu compet continu glucos monitor requir fingerstick confirm
late novemb us launch weve heard direct consum ad radio
mile white ceo earn call first expect demand pretti strong secondli market know
libr expect good strong block perform like describ
ad patient eu year launch
similar us ramp could yield mm rev
launch libr user grown
user current
new patient add
average patient per
refil
freestyl libr us launch could contribut bp total growth
debat nutrit swing hw tailwind
nutrit challeng year expect improv modestli pressur abat
recal china
venezuela
regul chang weigh china growth new
regul go effect jan limit brand
manufactur per plant
china licens manufactur
market growth hamper
us adult nutrit competit privat label
intensifi impact growth
return low singl growth nutrit could contribut bp overal growth
nutrit total
contribut total
nutrit grow low singl digit
could lift overal weight averag growth rate
ceo mile white comment call weve seen
market stabil china provid comfort
nutrit growth
pvt label competit histor last qs
annual competit mid eas pressur
nutrit posit contributor contribut bp abt growth
debat alin long term driver diagnost
consist grown market corelab new alin launch bode well continu momentum
share amongst big immunochemistri
seen chart consist grown
mid singl digit rang gain share
alin newest platform current
launch us stage
next year alin give competit edg
enabl dx segment continu
alin famili product major platform refresh promis compact footprint higher product
earli inning significantli enhanc
competit posit launch
alin highli differenti
innov suit new system mile
white ceo call
understand alin could long term driver enabl share gain
contract come renew bode well dx outlook next year
legaci alr bn rev revenu exposur segment
alr signific market share inf cardio
infecti diseas product treat type
diseas includ hiv influenza sti
fastest point care
diagnost test
rsv
assay min
long shelf-lif
deal close bring end complex transact
rest
alr deal announc feb amend apr
follow delay file part
deal final close oct mon post annc
divestitur arriva impact lower base bn
ev bn equiti valu bn
compani websit file evercor isi
debat alr could return growth
dx industri grow least msd sale growth struggl myriad issu impact
mail order diabet arriva one
troubl spot aler previous
ex arriva organ sale growth
cardio arriva tox pain pressur
dhr-bec case studi could take qs turnaround
acquir beckman coulter bn mid
time acquisit bec asset struggl
rev flat deal troponin-i fda recal
post deal close state diagnost grew
low singl digit rate organ fourth consecut
quarter low singl digit growth
sale grew mid-singl digit rate
think abl execut similar
dhr-bec expect alr grow
stj higher margin provid immedi mix benefit bp anoth bp impli synergi goal
assum legaci margin remain constant
mix benefit stj provid
immedi boost bp
full mm cost synergi
equat anoth margin expans
assum year synergi mm
ramp mm year stj
provid bp boost abt om
abt oper margin guidanc provid confid om expans medium term
guid om bp boost level
shown math execut stj synergi seem spot despit come much wors
legaci
benefit
bp
core
line guidanc
debat synergi goal come mm gmx key
alr drag om mix perspect origin synergi target could provid bp boost lt
busi chang materi
sinc issu mm
cost synergi target
mm divestitur well
alr origin synergi target mm equat alr sale
think expand base closer peer level
assum similar target lower revenu base bn ex divestitur arriva shut new synergi target
could mm translat bp margin expans opportun
synergi target sale seem high compar preced transact note gross margin
bp peer provid meaning oppti
typic deal contempl rev synergi target think could get
goal alr rev medium term via gm expans potenti
bp opportun medium term
alr trail peer significantli
manufactur facil geographi
alr play larg immunochemistri space see signific overlap manufactur
capabl technolog differ hurdl realiz manufactur synergi
shown manufactur footprint analysi think time abl consolid meaning
portion legaci alr howev manufactur consolid take year time post close think
alr synergi back end load fy
believ abl realiz signific manufactur relat synergi
could much opex save atyp deal howev expect
manuf relat synergi back end load fy
debat consist dd-teen tsr co
expect year stabil aler busi integr
diagnost portfolio alr return growth
expect alr relat synergi estim come mm
stj expect mm remain intact
alr front expect gross margin expans cog synergi nearli
high opex synergi atyp deal signific overlap capabl
current manufactur ineffici make us believ gross margin
expans realist outcom
mid singl digit top-line outlook bp oper margin expans
potenti de-lever cumul bn
dividend yield give confid consist doubl digit low teen
tsr compani medium term
invest thesi valuat framework
dcf pt equat tgr rang
revenu compound-annual-growth-rate period
ebita margin vs current margin
wacc
termin ebitda multipl rang
dcf rang impli termin growth rate tgr mid point
discount ebitda termin free flow enterpris alr total valu valu per perpetu growth valu enterpris enterpris valu januari
isi vs consensu valuat framework
isi vs st gener in-lin rev
isi vs st in-lin ep
dcf pt equat price-to-earnings base blend premium vs in-lin year average
pt impli blend price-to-earnings equat
premium vs in-lin recent year
pt impli equat in-lin larg cap
invest thesi risk
acceler top-line stori good visibl dd tsr initi outperform rate pt tsr
abt shape one best new product launch year could push organ top-line rang
acceler pf
virtual everi singl abt segment benefit new product eas industri pressur
legaci cardio larg stj busi ail given competit share loss de declin expect
share gain confirm rx icm launch continu growth mitraclip neuromod lvad drive bp increment
proprietari survey show mitrclip grow return growth
within legaci eas pressur nutrit success us launch freestyl libr could add anoth bp
us libr launch similar eu contribut mm increment revenu
final close alr see path bp margin expans along mid singl digit
top-line profil yield high singl doubl digit ebita growth along de-lever dividend see share
consist doubl digit teen tsr stori scarciti larg cap land
inabl regain share could pressur margin
headwind nutrit continu price pressur privat label
alr execut risk uncertain em fx environ difficult model given broad exposur em countri
could off-set synergi disappoint number vs st
epd drug busi blackbox st assum high singl doubl digit growth potenti hiccup could derail
note yield price-to-earnings multipl base current stock price evrisi estim
million except per share data fy end decemb organ gp less ep share inc net inc price-to-earnings prem disc januari
thank luck
medic suppli devic
healthcar facil manag
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst vijay kumar brittani henderson primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
